This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q1 Earnings Expected to Decline
by Zacks Equity Research
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
JAZZ Stock Surges Almost 30% YTD: What's Driving the Rally?
by Zacks Equity Research
Strong performance of JAZZ's Xywav and new oncology drugs along with acquired drugs reduced dependence on Xyrem, which will face generic competition shortly.
Axsome (AXSM) Surges on Potential Approval for AXS-05 Soon
by Zacks Equity Research
The FDA provides post-marketing requirements/commitments related to Axsome's (AXSM) under-review NDA for its lead pipeline candidate, AXS-05, for treating MDD. Investors anticipate an approval shortly.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
JAZZ Inks Deal With Werewolf to Add Oncology Candidate
by Zacks Equity Research
Jazz (JAZZ) signs an agreement to gain rights to Werewolf's engineered cytokine pro-drug candidate WTX-613. The candidate has the potential to treat a wide range of cancer types.
Jazz (JAZZ) Up 2.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: AXSM to Acquire JAZZ's Drug, IGMS Up on SNY Deal & More
by Zacks Equity Research
Acquisition and collaboration news from Axsome (AXSM) and IGM Biosciences, Inc. (IGMS), respectively, are a few key highlights from the biotech sector during the past week.
Axsome (AXSM) to Acquire Jazz's Sleep Disorder Drug, Sunosi
by Zacks Equity Research
Axsome (AXSM) inks an agreement with Jazz Pharmaceuticals to acquire the latter's new sleep disorder drug, Sunosi. The transaction is expected to close in the second quarter of 2022.
JAZZ Initiates Zepzelca Basket Study in Advanced Solid Tumors
by Zacks Equity Research
JAZZ enrolls the first patient in a mid-stage study to evaluate its lung cancer drug, Zepzelca, in advanced and difficult-to-treat cancer indications in previously-treated patients.
Jazz Pharmaceuticals (JAZZ) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
JAZZ Q4 Earnings Top, Sales Ride on New & Acquired Drugs
by Zacks Equity Research
JAZZ's product revenues grow in the fourth quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.
Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of 13.48% and 4.16%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen (IMGN) Q4 Earnings and Sales Outpace Estimates
by Zacks Equity Research
ImmunoGen (IMGN) reports a narrower-than-expected loss for fourth-quarter 2021. It also beats revenue estimates. Post the announcement, the share price rises.
Drug/Biotech Stocks' Q4 Earnings on Mar 1: PRGO, JAZZ & More
by Kinjel Shah
Let us look at five drug/biotech companies, PRGO, JAZZ, HZNP, SRPT and AXSM, which are gearing up for their earnings release.
Why Earnings Season Could Be Great for Jazz Pharmaceuticals (JAZZ)
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Jazz Pharmaceuticals (JAZZ) Stock a Suitable Value Pick Now?
by Zacks Equity Research
Let's see if Jazz Pharmaceuticals plc (JAZZ) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
4 Drug, Biotech Stocks Set to Beat Q4 Earnings Estimates
by Ekta Bagri
Let us take a look at some drug/biotech stocks like VIR, MRNA, JAZZ and ACAD that are poised to beat on fourth-quarter earnings.
Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zogenix (ZGNX) Stock Surges on Acquisition Offer From UCB
by Zacks Equity Research
Belgium-based UCB is set to acquire Zogenix (ZGNX) for a total transaction value of $1.9 billion in cash. The transaction is likely to be completed by second-quarter 2022.
Can Jazz (JAZZ) Climb 41% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 41.5% in Jazz (JAZZ). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Strength Seen in Jazz (JAZZ): Can Its 9% Jump Turn into More Strength?
by Zacks Equity Research
Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
JAZZ's Xywav Gets Orphan Drug Exclusivity for Hypersomnia
by Zacks Equity Research
The FDA bestows an Orphan Drug Exclusivity to Jazz's (JAZZ) Xywav for treating idiopathic hypersomnia in adults. This is the second Orphan Drug Exclusivity for the drug.
Jazz (JAZZ) Enrolls First Patient in Psychiatric Disorder Study
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) enrolls the first patient in a phase II study to evaluate JZP150 for treating adults with post-traumatic stress disorder.